Assoc. Prof. PharmDr. Jaroslav Roh, Ph.D.

Date and Place of Birth: 5. 5. 1983 in Jihlava, Czech Republic

Present Positions

Contact Information

  • Work Address: Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
  • E-mail: jaroslav.roh@faf.cuni.cz
  • Tel.: +420 495 067 339; Fax: +420 495 067 166

ORCID ID: 0000-0003-4698-8379
ResearcherID: S-7863-2017
Scopus Author ID: 16647003200

Education, positions, international experiences

  • since 2018 - Associate Professor at the Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University
  • 2013 - three months research stay at the University of Bath (UK) in the group of Dr. Ian M. Eggleston
  • 2008 - 2017 assistant professor at the Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University
  • 2007 - three month traineeship at State Technological Institute in St.Petersburg, (Russian federation) - supervisor Prof. G. I. Koldobskii
  • 2006-2010 - Doctoral study of Bioorganic chemistry at the Department of Inorganic and Organic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University in Prague
  • 2001-2006 - Master’s study of pharmacy at Faculty of Pharmacy in Hradec Králové, Charles University in Prague

Research interests

  • synthesis of potential antitubercular agents
  • synthesis of dexrazoxane analogues
  • (chemistry of nitrogen heterocycles)
  • (synthesis of hydrazone and thiosemicabazone-based iron chelators)

Teaching and popularization of science:

  • since 2008: supervisor of >15 M.Sc. (Pharmacy) diploma theses, co-supervisor of three Ph.D. students
  • since 2008: lecturer of General and Inorganic Chemistry study courses for B.Sc. and M.Sc. students (Pharmacy and Medical Bioanalytics), Chemical Laboratory Technique for M.Sc. students (Pharmacy), Charles University, Faculty of Pharmacy in Hradec Králové
  • 2014 - 2018 - organizer of “Postgraduate and Postdoc conference” at the Faculty of Pharmacy
  • Presentations “Science on the Faculty of Pharmacy” for Secondary schools
  • 2014 - 2017 - organizing of “Postgraduate and Postdoc conference” on the Faculty of Pharmacy

Scientific Grants

  • since 2019 – senior researcher in EU-funded project Pre-application research into innovative medicines and medical technologies (InoMed), reg. no. CZ.02.1.01/0.0/0.0/18_069/0010046

  • since 2018 - co-worker of ongoing Czech science foundation project 18-08169S - Study of individual topoisomerase II isoforms in anticancer and cardiotoxic effects of anthracyclines and their modulations by bisdioxopiperazines

  • 2014-2016 - co-worker of finished Czech science foundation project 14-08423S - Structure-activity-toxicity relationships studies in the group of small-molecule compounds with antimycobacterial activity - corresponding author of all resulting publications

  • 2014-2016 - Co-Principal and later Principal Investigator of finished Czech science foundation project 14-02165P

  • Co-worker of other 5 finished Czech science foundation projects:
    2013-2017 - 13-15008S - New potential cardioprotective agents: Study of structure-activity relationships in various types of myocardial injury
    2013-2017 - 13-23891S - Lipid membrane models – a new tool for studying pathophysiology of skin diseases at a molecular level
    GACR 203/07/1302; GACR 207/10/2048; GACR 207/11/0365

  • 2012-2017 - co-worker of Charles University Research Centre (UNCE 204019/304019/2012): Centre for the Study of Toxic and Protective Effects of Drugs on Cardiovascular System

  • 2012 - 2015 - co-worker in two EU-funded projects “Pre-seed activities of CU out of Prague“, reg. no. CZ.1.05/3.1.00/13.0284 and "Pre-seed activities of CU out of Prague II", reg. no. CZ.1.05/3.1.00/14.0299.

Awards obtained

Professional Memberships

Czech Chemical Society

Publications

author and co-author of 38 papers in international peer-reviewed journals, Σ IF > 139, >530 citations (WoS; excluding self-citations); H-index: 13 (WoS)

  1. L. V. Myznikov, J. Roh, T. V. Artamonova, A. Hrabálek, G. I. Koldobskii, Synthesis of 5-Substituted Tetrazoles under Microwave Activation. Russ. J. Org. Chem. 2007, 43 (5), 765-768. (IF2007 = 0.511)

  2. J. Roh,* T. V. Artamonova, K. Vávrová, G. I. Koldobskii, A. Hrabálek, Practical Synthesis of 5-Substituted Tetrazoles under Microwave Irradiation. Synthesis 2009, (13), 2175-2178. (IF2009 = 2.572)

  3. J. Roh,* K. Vávrová, A. Hrabálek. One-pot regioselective vinylation of tetrazoles: preparation of 5-substituted 2-vinyl-2H-tetrazoles. Tetrahedron Lett. 2010, 51 (10), 1411–1414. (IF2010 = 2.618)

  4. K. Vávrová, P. Kovaříková, B. Školová, M. Líbalová, J. Roh, R. Čáp, A. Holý, A. Hrabálek, Enhanced topical and transdermal delivery of antineoplastic and antiviral acyclic nucleoside phosphonate cPr‑PMEDAP. Pharm. Res. 2011; 28 (12), 3105-3115. (IF2011 = 4.093) (Q1)

  5. V. Novakova, J. Roh, P. Gela, J. Kuneš, P. Zimcik, Azaphthalocyanines with fused triazolo rings: formation of sterically stressed constitutional isomers. Chem. Commun. 2012, 48, 4326-4328. (IF2012 = 6.378) (Q1)

  6. J. Roh,* K. Vavrova, A. Hrabalek, Synthesis and Functionalization of 5-Substituted Tetrazoles, Eur. J. Org. Chem., 2012, 6101–6118. (IF2012 = 3.344) (Q1)

  7. B. Janůšová, B. Školová, K. Tükörová, L. Wojnarová, T. Šimůnek, P. Mladěnka, T. Filipský, M. Říha, J. Roh, K. Palát, A. Hrabálek, K. Vávrová, Amino acid derivatives as transdermal permeation enhancers. J. Control. Release 2013, 165 (2), 91-100. (IF2013 = 7.261) (Q1)

  8. L. Myznikov, U. Dmitrieva, T. Artamonova, J. Roh, A. Hrabálek, Y. Zevatskii, An Efficient Synthesis of 1-Substituted 5-Bromo-1H-tetrazoles. Synthesis 2013, 45, 2029-2033. (IF2013 =2.443)

  9. G. Karabanovich, J. Roh,* Z. Padělková, Z. Novák, K. Vávrová, A. Hrabálek, One-pot synthesis of 1-substituted-5-alkylselanyl-1H-tetrazoles from isoselenocyanates: Unexpected formation of N-alkyl-N-arylcyanamides and (Z)-Se-alkyl-N-cyano-N,N’-diarylisoselenoureas. Tetrahedron 2013, 69, 8798-8808. (IF2013 = 2.817)

  10. B. Školová, B. Janůšová, J. Zbytovská, G. Gooris, J. A. Bouwstra, P. Slepička, P. Berka, J. Roh, K. Palát, A. Hrabálek, K. Vávrová. Ceramides in the Skin Lipid Membranes: Length Matters. Langmuir 2013, 29, 15624-15633. (IF2013 = 4.384) (Q1)

  11. D. Diblikova, M. Kopecna, B. Skolova, M. Krecmerova, J. Roh, A. Hrabalek, K. Vavrova. Transdermal Delivery and Cutaneous Targeting of Antivirals using a Penetration Enhancer and Lysolipid Prodrugs. Pharm. Res. 2014, 31 (4), 1071-1081. (IF2014 = 3.420) (Q1)

  12. J. Stariat, V. Suprunova, J. Roh, V. Sestak, T. Eisner, T. Filipsky, P. Mladenka, M. Nobilis, T. Simunek, J. Klimes, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: Application to a pilot pharmacokinetic study in rats. Biomed. Chromatogr. 2014, 28 (5), 621-629. (IF2014 = 1.723)

  13. B. Skolova, K. Jandovska, P. Pullmannova, O. Tesar, J. Roh, A. Hrabalek, K. Vavrova. The Role of the Trans Double Bond in Skin Barrier Sphingolipids: Permeability and Infrared Spectroscopic Study of Model Ceramide and Dihydroceramide Membranes. Langmuir 2014, 30 (19), 5527-5535. (IF2014 = 4.457) (Q1)

  14. A. Kovacik, J. Roh, K. Vavrova. The Chemistry and Biology of 6-Hydroxyceramide, the Youngest Member of the Human Sphingolipid Family. ChemBioChem 2014, 15 (11), 1555-1562. (IF2014 = 3.088)

  15. G. Karabanovich, J. Roh,* T. Smutný, J. Něměcek, P. Vicherek, J. Stolaříková, M. Vejsová, I. Dufková, K. Vávrová, P. Pávek, V. Klimešová, A. Hrabálek. 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. Eur. J. Med. Chem. 2014, 82, 324-340. (IF2014 = 3.447) (Q1)

  16. B. Skolova, K. Hudska, P. Pullmannova, A. Kovacik, K. Palat, J. Roh, J. Fleddermann, I. Estrela-Lopis, K. Vavrova. Different Phase Behavior and Packing of Ceramides with Long (C16) and Very Long (C24) Acyls in Model Membranes: Infrared Spectroscopy Using Deuterated Lipids. J. Phys. Chem. B 2014, 118 (35), 10460-10470. (IF2014 = 3.302)

  17. G. Karabanovich, J. Roh,* O. Soukup, I. Pávková, M. Pasdiorová, V. Tambor, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek. Tetrazole Regioisomers in the Development of Nitro Group-Containing Antitubercular Agents. Med. Chem. Commun. 2015, 6, 174-181. (IF2015 = 2.319)

  18. L. Lochman, J. Svec, J. Roh, V. Novakova. The role of the size of aza-crown recognition moiety in azaphthalocyanine fluorescence sensors for alkali and alkaline earth metal cations. Dyes Pigment. 2015, 121, 178-187. (IF2015 = 4.055) (Q1)

  19. A. Jirkovska, J. Roh, O. Lenčová-Popelová, E. Jirkovsky, K. Hruskova, E. Potuckova, H. Jansova, P. Haskova, P. Martinkova, T. Eisner, M. Kratochvil, J. Sus, M. Machacek, L. Tichotova, V. Gersl, D. S. Kalinowski, M. Muller, D. Richardson, K. Vavrova, M. Sterba, T. Simunek. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicol. Res. 2015, 4, 1098–1114. (IF2015 = 2.161)

  20. E. Potůčková, J. Roh, M. Macháček, S. Sahni, J. Stariat, V. Šesták, H. Jansová, P. Hašková, A. Jirkovská, K. Vávrová, P. Kovaříková, D. S. Kalinowski, D. R. Richardson, T. Šimůnek. In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS ONE 2015, 10 (10). e0139929. (IF2015 = 3.057) (Q1)

  21. L. Opálka, A. Kováčik, M. Sochorová, J. Roh, J. Kuneš, J. Lenčo, K. Vávrová. Scalable Synthesis of Human Ultralong Chain Ceramides. Org. Lett., 2015, 17 (21), 5456–5459. (IF2015 = 6.732) (Q1)

  22. V. Sestak, J. Stariat, J. Cermanova, E. Potuckova, J. Chladek, J. Roh, J. Bures, H. Jansova, P. Prusa, M. Sterba, S. Micuda, T. Simunek, D. S. Kalinowski, D. R. Richardson, P. Kovarikova. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget, 2016, 6 (40), 42411-42428. (IF2016 = 5.168) (Q1)

  23. L. Lochman, J. Svec, J. Roh, K. Kirakci, K. Lang, P. Zimcik, V. Novakova. Metal-Cation Recognition in Water by a Tetrapyrazinoporphyrazine-Based Tweezer Receptor. Chem. Eur. J., 2016, 22(7), 2417-2426. (IF2016 = 5.317) (Q1)

  24. G. Karabanovich, J. Zemanová, T. Smutný, R. Székely, M. Šarkan, I. Centárová, A. Vocat, I. Pávková, P. Čonka, J. Němeček, J. Stolaříková, M. Vejsová, K. Vávrová, V. Klimešová, A. Hrabálek, P. Pávek, S. T. Cole, K. Mikušová, J. Roh.* Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-Oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2016, 59, 2362−2380. (IF2016 = 6.259) (Q1)

  25. V. Sestak , J. Roh, L. Klepalova, P. Kovarikova. A UHPLC-UV-QTOF Study on the Stability of Carfilzomib, A Novel Proteasome Inhibitor. Journal of Pharmaceutical and Biomedical Analysis, 2016, 124, 365–373. (IF2016 = 3.255) (Q1)

  26. H. Jansová, J. Bureš, M. Macháček, P. Hašková, A. Jirkovská, J. Roh, Q. Wang, K. J. Franz, P. Kovaříková, T. Šimůnek. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350, 15–24. (IF2016 = 3.582) (Q1)

  27. A. Kováčik, L. Opálka, M. Šilarová, J. Roh, K. Vávrová. Synthesis of 6-hydroxyceramide using rutheniumcatalyzed hydrosilylation–protodesilylation. Unexpected formation of a long periodicity lamellar phase in skin lipid membranes. RSC Advances, 2016, 6, 73343–73350. (IF2016 = 3.108)

  28. J. Roh,* G. Karabanovich, V. Novakova, T. Šimůnek, K. Vávrová. Large-scale synthesis of piperazine-2,6-dione and its use in the synthesis of dexrazoxane analogues. Synthesis. 2016, 48, 4580-4588. (IF2016 = 2.650)

  29. G. Karabanovich, J. Němeček, L. Valášková, A. Carazo, K. Konečná, J. Stolaříková, A. Hrabálek, O. Pavliš, P. Pávek, K. Vávrová, J. Roh,* V. Klimešová. S-Substituted 3,5-Dinitrophenyl 1,3,4-Oxadiazole-2-thiols and Tetrazole-5-thiols as Highly Efficient Antitubercular Agents. Eur. J. Med. Chem. 2017, 126, 369-383. (IF2017 = 4.816) (Q1)

  30. J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh,* V. Klimešová. Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents. Eur. J. Med. Chem. 2017, 130, 419–432. (IF2017 = 4.816) (Q1)

  31. E. Mezeiova, J. Korabecny, V. Sepsova, M. Hrabinova, P. Jost, L. Muckova, T. Kucera, R. Dolezal, J. Misik, K. Spilovska, N. L. Pham, L. Pokrievkova, J. Roh, D. Jun, O. Soukup, D. Kaping, K. Kuca. Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy. Molecules 2017, 22, 1265. (IF2017 = 3.098)

  32. J. Roh *, G. Karabanovich, H. Vlčková, A. Carazo, J. Němeček, P. Sychra, L. Valášková, O. Pavliš, J. Stolaříková, V. Klimešová, K. Vávrová, P. Pávek, A. Hrabálek. Development of Water-Soluble 3,5-Dinitrophenyl Tetrazole and Oxadiazole Antitubercular Agents. Bioorg. Med. Chem. 2017, 25, 5468–5476. (IF2017 = 2.881)

  33. I. Melnikova, J. Roh, J. Kuneš, T. Artamonova, Y. Zevatskii, L. Myznikov. Non-catalyzed addition of heterocyclic thiols and 5-substituted-1H-tetrazoles to vinyl ethers. Tetrahedron Lett. 2017, 58, 3842–3845. (IF2017 = 2.125)

  34. J. Bureš, A. Jirkovská, V. Šesták, H. Jansová, G. Karabanovich, J. Roh, M. Štěrba, T. Šimůnek, P. Kovaříková. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology 2017, 392, 1-10. (IF2017 = 3.265)

  35. E. Jirkovský, A. Jirkovská, J. Bureš, J. Chládek, O. Lenčová, J. Stariat, Z. Pokorná, G. Karabanovich, J. Roh, P. Brázdová, T. Šimůnek, P. Kovaříková, M. Štěrba. Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart. 2018, (IF2017 = 3.706) (Q1)

  36. , , , , , and 2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress. Chem. Res. Toxicol., 2018, 31 (11), 1151–1163. (IF2017 = 3.432) (Q1)

  37. P. Reimerova, A. Jirkovska, H. Piskackova, G. Karabanovich, J. Roh, T. Simunek, P. Sterbova-Kovarikova. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.  Sci. Rep. 2019, 9, Art. No. 4524. (IF2017 = 4.122) (Q1)

  38. P. Reimerova; J. Stariat, H. Piskackova, H. Jansova, J. Roh, D.S. Kalinowski, M. Machacek, T. Simunek, D. R. Richardson, P. Sterbova-Kovarikova. Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. Anal. Bioanal. Chem. 2019, 411(11), 2383-2394. (IF2017 = 3.307) (Q1)

Patents and patent applications

  1. CZ 305622 B6. Hrabálek A., Roh J., Karabanovich G., Klimešová V., Němeček J., Pávek P.: Substituovaný tetrazol, jeho použití a farmaceutický přípravek ho obsahující.

  2. CZ 305680 B6. Hrabálek A., Roh J., Karabanovich G., Klimešová V., Němeček J., Pávek P.: Substituovaný diazol, jeho použití a farmaceutický přípravek ho obsahující.

  3. WO 2014/161516 (PCT/CZ2013/000131). Hrabálek A., Roh J., Karabanovich G., Klimešová V., Němeček J., Pávek P.: Oxa- and thia-diazoles useful in the treatment of Tuberculosis.

  4. CZ 306408 B6. Karabanovich G., Roh J., Hrabálek A., Klimešová V., Pávek P.: Dinitrofenyl oxadiazol a triazol, jeho použití a farmaceutický přípravek ho obsahující.

  5. CZ 306245 B6. Roh J., Němeček J., Hrabálek A., Klimešová V., Karabanovich G., Pávek P., Sychra P.: Substituovaný fenyltetrazol, jeho použití a farmaceutický přípravek ho obsahující.

  6. CZ 306321 B6. Němeček J., Roh J., Hrabálek A., Klimešová V., Karabanovich G., Pávek P.: Substituovaný dinitrofenyltetrazol, jeho použití a farmaceutický přípravek ho obsahující.

  7. WO2016/091228 A1 (PCT/CZ2015/000126) Roh J., Němeček J., Hrabálek A., Klimesova V., Karabanovich G., Pavek P., Sychra P. Substituted phenyltetrazole, its use and pharmaceutical preparation containing the same.

  8. PV 2015-444. Substituovaný nitrobenzyltetrazol, jeho použití a farmaceutický přípravek ho obsahující. Čonka P., Hrabálek A., Karabanovich G., Němeček J., Klimešová V., Valášková L., Roh. J.

  9. PV 2018-664. Substituovaný 1,2,4-oxadiazol, jeho použití a farmaceutický přípravek ho obsahující (Substituted 1,2,4-oxadiazole, its use and pharmaceutical preparation containing the same). Roh. J., Karabanovich G., Pavek P., Hrabálek A. - bought by Svenox Pharmaceuticals LLC

© Univerzita Karlova, Farmaceutická fakulta v Hradci Králové, Akademika Heyrovského 1203, 500 05 Hradec Králové, Česká republika
O webu a cookies | Powered by Kentico